BME announces launch of Speed Arc Nitinol Fixation System

NewsGuard 100/100 Score

BioMedical Enterprises (BME) announced the launch of the Speed Arc Nitinol Fixation System, the world's first superelastic shape memory fixation device that conforms to the sloping surface of the metaphyseal anatomy. This addition to the current patented BME Speed Fixation System is available in three different sizes to ensure a proper fit in varying patient anatomies.

Ideal for proximal and distal Akin osteotomies of the foot, the Speed Arc has the same great features as BME's current Speed system: constant compression to optimize healing, implant pre-loaded on a patent-pending insertion tool for ease of use and pre-sterilized, disposable instrumentation for simplified operating room logistics.

"The launch of the Speed Arc implant is yet another testament to BME's commitment to providing technical advancements in every new product we release to the market. We will continue to set the bar higher to meet customer expectations with our innovative products."

Dr. John Anderson, DPM, FACFAS, Podiatry Associates of Florida stated, "BME, a leader in Nitinol fixation in extremity surgery, is leading the way in developing implants that not only allow for continuous compression, but also contour to the slope or position of the bone. That is exactly what they have accomplished with the Speed Arc Staple. With the combined advancement of the contouring slope (anatomical design) of the implant and the continuous compression afforded by BME's Nitinol fixation, the Speed Arc offers an excellent solution for fusions and osteotomies for any surgeon."

The new BME Speed Arc Nitinol Fixation System is available now for commercial use throughout the United States.

Source:

BME, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Early warning sign for myeloma found in bone marrow fat cells